Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.

Kittitat ChiaranairungrotKomkrich KaewpreechawatChanwit SajaiNarueporn PagowongNissa SukaratPokpong PiriyakhuntornThanawat RattanathammetheeSasinee HantrakoolChatree Chai-AdisaksophaAdisak TantiworawitLalita NorasetthadaEkarat Rattaritamrong

Published in: Hematology (Amsterdam, Netherlands) (2022)

The prevalence of HU resistance or intolerance in PV and ET patients was 11.9%. Patients with HU resistance or intolerance significantly increased the risk of bleeding complications.

Keyphrases

risk factors
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
atrial fibrillation
patient reported outcomes
patient reported